Design and synthesis of novel CCR3 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 20, 2003, Pages 3597-3600

  Gong, Leyi ^a   Hogg, J Heather ^a   Collier, James ^a   Wilhelm, Robert S ^a   Soderberg, Carol ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMOKINE RECEPTOR CCR3; NITROGEN; PIPERIDINE DERIVATIVE;

ARTICLE; BINDING ASSAY; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; STRUCTURE ACTIVITY RELATION;

EID: 0141516669     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00748-0     Document Type: Article

References (14)

1. Busse W.W., Lamanke R.F. Jr. N. Engl. J. Med. 344:2001;350.
2. Oppenheim J., Feldman M. Cytokine Reference. 2001;Academic, London. Vol. 1, p 3.
3. Daugherty B.L., Siciliano S., Demartino J.A., Malkowitz L., Sirontina A., Springer M.S. J. Exp. Med. 183:1996;2349.
4. Sallusto F., Mackay C.R., Lanzavecchia A. Science. 277:1997;2005.
5. Ochi H., Hirani W.M., Yuan Q., Friend D.S., Austen K.F., Boyce J.A. J. Exp. Med. 190:1999;267.
6. Bryan, S. A.; Ponath, P. D.; Wilhelm, R. S. In New Drugs for Asthma, Allergy and COPD; Hansel, T. T., Barnes, P. J., Eds.; Karger: Basel, 2001; Vol. 31, p 288.
7. Naya, A; Sagara, Y.; Ohwaki, K.; Saeki, T.; Ichikawa, D.; Iwasawa, Y.; Noguchi, K.; Ohtake, N. J. Med. Chem. 2001, 44, 1429.
8. Dhanak D., Christmann L.T., Darcy M.G., Jurewicz A.J., Keenan R.M., Lee J., Sarau H.M., Widdowson K.L., White J.R. Bioorg. Med. Chem. Lett. 11:2001;1441.
9. Naya A., Kobayashi K., Ishikawa M., Ohwaki K., Saeki T., Noguchi K., Ohtake N. Bioorg. Med. Chem. Lett. 11:2001;1219.
10. Kato M., Ito K., Nishino S., Yamakuni H., Takasugi H. Chem. Pharm. Bull. 43:1995;1351.
11. 5 of the CCR3 L1.2 transfected cells in 25 μL binding buffer. After incubation for 1 h at rt, the reaction was terminated by filtering through polyethyenimine treated Packard Unifilter GF/C filter plate. The filters were washed 5 times with ice cold wash buffer containing 10 mM HEPES and 0.5 M NaCl (pH 7.2) and dried at 65°C for 30 min. 25 μL/well of Microscint-20™ scintillation fluid was added and the radioactivity retained on the filters was determined by using the Packard TopCount™.
12. Mirzadegan T., Diehl F., Ebi B., Bhakta S., Polsky I., McCarley D., Mulkins M., Weatherhead G.S., Lapierre J.M., Dankwardt J., Morgans D. Jr., Wilhelm R., Jarnagin K. J. Biol. Chem. 275:2000;25562.
13. Manuscript in preparation.
14. The CCR3 antagonist activity can also be determined by measuring the inhibition of eotaxin mediated chemotaxis of the CCR3 L1.2 transfectant cells using the method described by: Ponath P.D., Qin S., Ringler D.J., Clark-Lewis I., Wang J., Kassam N., Smith H., Shi X., Gonzalo J., Newman W., Gutierrez-Ramos J., Mackay C.R. J. Clin. Invest. 97:1996;604.